Onpode
Cover art for Livsayis (cemdisiran) is the second new MG drug approved this week—but its siRNA mechanism is entirely novel

Livsayis (cemdisiran) is the second new MG drug approved this week—but its siRNA mechanism is entirely novel

November 20, 2026 · 8 min

Cole Brennan & Malcolm Reeves

Hey — rough week, good week, I genuinely cannot tell anymore, but I found something that made the whole thing better. What did you find? An FDA approval that — okay, the approval itself is not the weird part. Livsayis, cemdisiran, Regeneron, November 18th 2026, generalized myasthenia gravis. Four shots a year. First siRNA in…

On November 18, 2026, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This marks the first small-interfering RNA (siRNA) therapy approved for gMG, as well as Regeneron's first approved medicine in both neurology and the siRNA modality.

0:008:20
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

On November 18, 2026, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This marks the first small-interfering RNA (siRNA) therapy approved for gMG, as well as Regeneron's first approved medicine in both neurology and the siRNA modality.

Grounded in 11 sources
Myasthenia gravis: innovative therapies and new frontiers in research | Drugs & Therapy Perspectives | Springer Nature Link ↗ · link.springer.com
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis | AJMC ↗ · ajmc.com
Cemdisiran: First siRNA Therapy for Myasthenia Gravis ↗ · allsci.com
FiercePharma covers Regeneron’s entry into neurology via Livsayis ↗ · fiercepharma.com
Regeneron’s siRNA Therapy to Myasthenia Gravis Delivers in Phase III Trial | Inside Precision Medicine ↗ · insideprecisionmedicine.com
Regeneron wins FDA approval for Livsayis (cemdisiran) ↗ · investor.regeneron.com
Novel Therapies for Generalized Myasthenia... : American Journal of Therapeutics ↗ · ovid.com
Cemdisiran Approved as First siRNA Therapy for Myasthenia Gravis | Pharmacy Times ↗ · pharmacytimes.com
Unmet Needs in Myasthenia Gravis: What KOLs Say Must Change | REACH MarketVue® ↗ · reachmr.com
Myasthenia Gravis Drug Livsayis: FDA Clears Quarterly RNA Shot, Boxed Infection Warning Stays ↗ · techtimes.com
Alnylam receives $25M milestone on Livsayis approval ↗ · x.ai
Read transcript

Cole Brennan: Hey — rough week, good week, I genuinely cannot tell anymore, but I found something that made the whole thing better.

Malcolm Reeves: What did you find?

Cole Brennan: An FDA approval that — okay, the approval itself is not the weird part. Livsayis, cemdisiran, Regeneron, November 18th 2026, generalized myasthenia gravis. Four shots a year. First siRNA in this disease. All legitimately notable.

Malcolm Reeves: Right — and Regeneron's first neurology approval, full stop. George Yancopoulos called it a landmark. That's not a word he reaches for casually.

Cole Brennan: But here's what doesn't add up — the NIMBLE trial, largest global interventional gMG trial ever run, tested cemdisiran alone AND paired with pozelimab. Both arms. Full study. And Regeneron walks up to the FDA and says... just give us the monotherapy.

Malcolm Reeves: Now that — that is an editorial decision that requires an explanation. You do not run what they're calling the largest interventional trial in this disease's history and then quietly shelve half your data without a reason.

Cole Brennan: And neither of us has a clean answer yet.

Malcolm Reeves: No. And that is exactly where we start.

Cole Brennan: But before we get into why they shelved the combo label — I want to make sure we've actually explained what cemdisiran even does, because I think most people hear 'gene silencing' and go blank. Like, the simplest version: existing drugs like eculizumab catch the harmful protein after it's already been shipped out. Cemdisiran goes to the factory floor — specifically your liver — and stops the order from ever being printed.

Malcolm Reeves: The mRNA gets degraded. Before the C5 protein is ever made.

Cole Brennan: Right — so eculizumab, ravulizumab, they're catching boxes at the loading dock. Cemdisiran is upstream of that. The box never gets packed.

Malcolm Reeves: And yet — structurally cleaner does not automatically mean clinically superior.

Cole Brennan: No, that's — yeah, that's the thing that's genuinely unresolved. Because mechanistically it feels like a leap forward, but the NIMBLE data, I mean, we don't have a head-to-head against eculizumab sitting right there proving it.

Malcolm Reeves: Now here is what complicates the 'first siRNA in this disease' framing further — Regeneron did not originate the molecular tool. Alnylam Pharmaceuticals received a milestone payment when Livsayis got approved. There is a licensing relationship underneath this.

Cole Brennan: Wait — Alnylam got paid on the approval date itself?

Malcolm Reeves: On approval. Which means the siRNA patent estate — the core mechanism Regeneron is now getting credit for pioneering in gMG — that belongs to someone else's house. Regeneron is the first to bring it to this disease. But they are not the inventor of the key.

Cole Brennan: But that's the part that actually breaks my brain a little — because if the mechanism is cleaner upstream, why do REACH MarketVue neurologist surveys still come back saying the gMG landscape is incompletely treated? Like, three C5 protein-blockers already approved — eculizumab, ravulizumab, zilucoplan — and KOLs are still saying we're not there.

Malcolm Reeves: And that's before you count the FcRn class. Efgartigimod, Vyvgart, approved. Inebilizumab, Uplizna — a CD19 B-cell depleter, entirely different mechanism. Seven-plus approved therapies, and neurologists are still unsatisfied. That is not a small data point.

Cole Brennan: Seven-plus. That's — yeah, that's a crowded room.

Malcolm Reeves: Now picture the patient Tuan Vu — professor at the University of South Florida Morsani, global principal investigator on NIMBLE — picture the patient he's actually trying to reach. AChR-antibody-positive. Already on background immunosuppressive therapy. Cycled through two FcRn inhibitors. Still can't climb a full flight of stairs. What does cemdisiran open for her that the three prior C5 blockers did not?

Cole Brennan: And that's — wait, that scope matters actually. The FDA approval is narrow. AChR-antibody-positive adults, background immunosuppression. That's not all gMG. So Regeneron isn't even claiming to fix the whole room.

Malcolm Reeves: Correct. And that is the clinical question Vu has to answer honestly — does silencing C5 gene expression in the liver open genuinely new ground for her, or does it just offer a less burdensome path to the same ceiling those three C5 protein-blockers already hit?

Cole Brennan: Four shots a year instead of infusions, home administration — I mean, that's real, that matters. But it's not the same as a new mechanism of action opening new patients to remission.

Malcolm Reeves: No. Convenience is not efficacy. And that distinction — the ceiling question — gets much harder to avoid when you get to what Regeneron chose not to pursue on the label. That part, and the class-wide boxed warning that every C5 inhibitor carries for Neisseria meningitidis infection, those are the two structural ceilings on real-world uptake we haven't touched yet.

Cole Brennan: Right — and I think one of those ceilings is higher than people realize. We'll get there.

Malcolm Reeves: Both ceilings at once — that's the frame. And the meningococcal one is deceptively simple on paper. Cemdisiran carries a boxed warning for serious Neisseria meningitidis infections. Every complement inhibitor carries that warning. Class-wide. So it's not a strike against cemdisiran specifically. But it means every single prescribing decision starts with: has this patient been vaccinated, or are they on antibacterial prophylaxis? That's a gatekeeping step before the drug ever enters the conversation.

Cole Brennan: Every patient. No exceptions.

Malcolm Reeves: Every patient. And in a busy neurology practice — the kind Tuan Vu runs — that administrative friction shapes who gets offered the drug in the first place. Not because the drug is dangerous relative to its class, but because the box is there, and it requires documentation.

Cole Brennan: Okay but — and this is where the missing combo label hits differently — if you've already got that meningococcal gatekeeping in place, you've already done the hard administrative work for the patient. Cemdisiran is in. So why wouldn't you then layer pozelimab on top? The mechanistic rationale is almost embarrassingly clean: cemdisiran silences C5 gene expression upstream in the liver, pozelimab mops up whatever circulating C5 protein is still floating around downstream. That's not redundant, that's layered. NIMBLE actually ran that arm through week 24.

Malcolm Reeves: And improvements emerged as early as week 2 in that trial.

Cole Brennan: Week 2 — which is fast for gMG. So they have the data, they have the mechanistic story, and Regeneron just... doesn't walk that to the FDA. I mean, some people would say that's a business call dressed as a science call. And then Citi analysts describe the approval as 'strategically important' — strategically, not clinically — and suddenly that framing makes a lot more sense.

Malcolm Reeves: Now — 'strategically important' is Citi's language, not the FDA's. And what it's tracking is pipeline value, not whether the combination moved the needle on disease outcomes. Which is actually the question we can't answer, because we don't know what the combination data showed. The sources don't say. And that silence is the signal.

Cole Brennan: That's — yeah, the silence. Because if the combo arm showed something dramatically better, you pursue the label. If it showed no meaningful advantage over monotherapy, you don't add regulatory complexity for no clinical gain. And if it showed something... murky, you definitely don't hand that to the FDA voluntarily. We just don't know which of those it was.

Malcolm Reeves: And that is the efficacy ceiling question that sits underneath the whole approval. Cemdisiran as monotherapy is real. The siRNA mechanism is real. The Neisseria meningitidis warning is manageable. But the combination story — the most mechanistically elegant version of this drug — remains unresolved. And that's what a neurologist inherits when she reaches for the prescription pad.

Cole Brennan: And that's — I keep trying to find a way to settle it, and I can't. The two-year window is the only honest test. If cemdisiran is first-line for AChR-positive gMG within two years, then the siRNA mechanism actually changed something fundamental. If it ends up as the option for patients who can't do infusion schedules, then... the administrative advance was real, but the breakthrough framing got ahead of the data.

Malcolm Reeves: And that's genuinely open. Regeneron's first siRNA, first neurology approval — the weight of that framing depends entirely on what the post-approval prescribing looks like. We won't know for a while. The missing combination label is the thing I cannot set down. Because if the ceiling is lower than the siRNA story implies, that's the data Regeneron already has and chose not to show.

Cole Brennan: Yeah. The silence does the talking. I'll sit with that one for a bit.